Reply to Comment on "Market Exclusivity for Drugs with Multiple Orphan Approvals (1983-2017) and Associated Budget Impact in the US".
作者信息
Padula William V, Parasrampuria Sonal, Socal Mariana P, Conti Rena M, Anderson Gerard F
机构信息
Department of Pharmaceutical and Health Economics, School of Pharmacy, USC Schaeffer Center, University of Southern California, 635 Downey Way, Los Angeles, CA, 90089, USA.
Leonard D. Schaeffer Center for Health Policy and Economics, University of Southern California, Los Angeles, CA, USA.
出版信息
Pharmacoeconomics. 2020 Dec;38(12):1375-1376. doi: 10.1007/s40273-020-00973-9. Epub 2020 Nov 9.
Abstract
摘要
相似文献
1
Reply to Comment on "Market Exclusivity for Drugs with Multiple Orphan Approvals (1983-2017) and Associated Budget Impact in the US".对《具有多项孤儿药批准的药物的市场独占权（1983 - 2017年）及其在美国的相关预算影响》评论的回复
Pharmacoeconomics. 2020 Dec;38(12):1375-1376. doi: 10.1007/s40273-020-00973-9. Epub 2020 Nov 9.
2
Comment on "Market Exclusivity for Drugs with Multiple Orphan Approvals (1983-2017) and Associated Budget Impact in the US".关于《美国具有多项孤儿药批准的药物的市场独占权（1983 - 2017年）及相关预算影响》的评论
Pharmacoeconomics. 2020 Dec;38(12):1373-1374. doi: 10.1007/s40273-020-00975-7. Epub 2020 Nov 9.
3
Market Exclusivity for Drugs with Multiple Orphan Approvals (1983-2017) and Associated Budget Impact in the US.具有多种孤儿药批准的药物的市场独占权（1983-2017）及其在美国的相关预算影响。
Pharmacoeconomics. 2020 Oct;38(10):1115-1121. doi: 10.1007/s40273-020-00934-2.
4
Estimating the budget impact of orphan medicines in Europe: 2010 - 2020.估算欧洲孤儿药的预算影响：2010-2020 年。
Orphanet J Rare Dis. 2011 Sep 27;6:62. doi: 10.1186/1750-1172-6-62.
5
Modifying the Criteria for Granting Orphan Drug Market Exclusivity.修改授予孤儿药市场独占权的标准。
Value Health. 2020 Nov;23(11):1470-1476. doi: 10.1016/j.jval.2020.08.004. Epub 2020 Sep 28.
6
Effective Market Exclusivity of New Molecular Entities for Rare and Non-rare Diseases.新分子实体在罕见病和非罕见病方面的有效市场独占权。
Pharmaceut Med. 2020 Feb;34(1):19-29. doi: 10.1007/s40290-019-00317-9.
7
Incentives for orphan drug research and development in the United States.美国孤儿药研发的激励措施。
Orphanet J Rare Dis. 2008 Dec 16;3:33. doi: 10.1186/1750-1172-3-33.
8
Budget impact analysis of drugs for ultra-orphan non-oncological diseases in Europe.在欧洲，用于超孤儿非肿瘤疾病的药物的预算影响分析。
Expert Rev Pharmacoecon Outcomes Res. 2015 Feb;15(1):171-9. doi: 10.1586/14737167.2015.965156. Epub 2014 Oct 14.
9
Patient Accessibility and Budget Impact of Orphan Drugs in South Korea: Long-Term and Real-World Data Analysis (2007-2019).韩国孤儿药的患者可及性和预算影响：长期真实世界数据分析（2007-2019）。
Int J Environ Res Public Health. 2020 Apr 26;17(9):2991. doi: 10.3390/ijerph17092991.
10
Evaluating The Impact Of The Orphan Drug Act's Seven-Year Market Exclusivity Period.评估《孤儿药法案》七年市场独占期的影响。
Health Aff (Millwood). 2018 May;37(5):732-737. doi: 10.1377/hlthaff.2017.1179.
本文引用的文献
1
Modifying the Criteria for Granting Orphan Drug Market Exclusivity.修改授予孤儿药市场独占权的标准。
Value Health. 2020 Nov;23(11):1470-1476. doi: 10.1016/j.jval.2020.08.004. Epub 2020 Sep 28.
2
Market Exclusivity for Drugs with Multiple Orphan Approvals (1983-2017) and Associated Budget Impact in the US.具有多种孤儿药批准的药物的市场独占权（1983-2017）及其在美国的相关预算影响。
Pharmacoeconomics. 2020 Oct;38(10):1115-1121. doi: 10.1007/s40273-020-00934-2.
3
Estimation of clinical trial success rates and related parameters.临床试验成功率及相关参数的估计。
Biostatistics. 2019 Apr 1;20(2):273-286. doi: 10.1093/biostatistics/kxx069.
4
Obstacles to the Adoption of Biosimilars for Chronic Diseases.慢性病生物类似药采用过程中的障碍。
JAMA. 2017 Jun 6;317(21):2163-2164. doi: 10.1001/jama.2017.5202.
Zotero 插件